Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ Adenocarcinoma

NCT ID: NCT06932068

Last Updated: 2025-04-17

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 77 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-03-26
• Study Completion Date: 2027-10-31

Brief Summary

This is single - arm study to explore the safety and efficacy of iparomlimab and tuvonralimab (QL1706) combined with chemotherapy for treating her2-negative, low PD-L1 expressing, unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma

Conditions

HER2 Negative; Low PD-L1 Expressing; Unresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

QL1706 + XELOX chemotherapy

Iparomlimab and Tuvonralimab+XELOX

Group Type: EXPERIMENTAL

Iparomlimab and Tuvonralimab (QL1706)

Intervention Type: DRUG

5 mg/kg, ivdrip, Day 1, Q3W, until progressive disease or intolerable toxicity.

Oxallplation

Intervention Type: DRUG

130 mg/m2, ivdrip, Day 1, Q3W, for the first 6 cycles.

Capectitabine Tablets

Intervention Type: DRUG

1000 mg/m2, po, bid, Days 1-14, Q3W, until progressive disease or intolerable toxicity.

Interventions

Iparomlimab and Tuvonralimab (QL1706)

5 mg/kg, ivdrip, Day 1, Q3W, until progressive disease or intolerable toxicity.

Intervention Type: DRUG

Oxallplation

130 mg/m2, ivdrip, Day 1, Q3W, for the first 6 cycles.

Intervention Type: DRUG

Capectitabine Tablets

1000 mg/m2, po, bid, Days 1-14, Q3W, until progressive disease or intolerable toxicity.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Aged 18-75 years, gender is not limited;

2. Pathologically confirmed locally advanced gastric or gastroesophageal junction adenocarcinoma that is inoperable or has distant metastasis;

3. HER2-negative by immunohistochemistry (IHC);

4. low PD-L1 expression status (CPS < 5);

5. Has at least 1 measurable lesion as determined by RECIST 1.1;

6. No systematic treatment in the past, or the patient has received neoadjuvant/adjuvant chemotherapy, but the disease progresses or relapses more than 6 months after the end of treatment;

7. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;

8. Adequate organ function;

9. The life expectancy is at least 3 months;

10. Willing to join the study and signed an informed consent form (ICF) with good compliance and cooperation in follow-up.

Exclusion Criteria

1. Allergic to any trial drug and its excipients, or serious allergy history, or contraindication of the trial drug;

2. Cardiovascular and cerebrovascular events that are not well controlled;

3. Has received systematic treatment with Chinese patent medicine or immunomodulatory drugs (including thymosin, interferon, interleukin, except for local use for ascites control) before the first administration within 2 weeks;

4. Have a history of interstitial lung disease, non-infectious pneumonia, pulmonary fibrosis, acute lung disease, or systemic disease with poor control (including but not limited to diabetes, hypertension, etc.);

5. Have a history of active immune deficiency or autoimmune diseases, including HIV positive test, or have other acquired or congenital immune deficiency diseases, or have a history of organ transplantation or autoimmune diseases;

6. Severe chronic or active infection requires systemic antibacterial, antifungal or antiviral treatment, including tuberculosis infection.Have a history of active tuberculosis infection ≥ 1 year before recruitment should also be excluded, unless proved has been completed appropriate treatment;

7. Brain metastasis or leptomeningeal metastasis;

8. Clinically significant pleural effusion, pericardial effusion or ascites should be drained for many times within 2 weeks before the first administration of the trial drug;

9. Has a second clinically detectable primary malignant tumor at the time of recruitment, or there were other malignant tumors in the past 5 years (except for fully treated skin basal cell carcinoma or cervical carcinoma in situ);

10. Any major surgery was performed ≤ 28 days before the first trial drug administration;

11. History of allogeneic stem cell transplantation or organ transplantation;

12. Duodenal ulcer, ulcerative colitis, intestinal obstruction and other gastrointestinal diseases at present; or other conditions that may cause gastrointestinal bleeding or perforation judged by the researchers; or history of intestinal perforation or fistula, but has not recovered after surgical treatment;

13. Live vaccine was inoculated within 4 weeks (inclusive) before the first administration of the trial drug, not including seasonal influenza vaccines but intranasal vaccine.

14. Has other factors that may lead to the forced termination of this trial according to the judgment of the investigator, such as other serious diseases (including psychological and mental diseases) requiring combined treatment, serious laboratory examination abnormalities, and family or social factors, which may affect the safety of the subject, or the collection of data and samples;

15. Participating in other therapeutic clinical studies or using research instruments within 4 weeks before the first administration;

16. Others conditions do not meet the inclusion according to the judgment of the investigator.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Qilu Hospital of Shandong University

OTHER

Sponsor Role: lead

Responsible Party

Lian Liu, MD, PHD

Director of Department of Oncology

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Lian Liu, MD, PHD

Role: PRINCIPAL_INVESTIGATOR

Qilu Hospital of Shandong University

Locations

Qilu Hospital of Shandong University

Jinan, Shandong, China

Site Status: RECRUITING

Countries

China

Central Contacts

Lian Liu, MD, PHD

Role: CONTACT

tounao@126.com

0531-82169851

Song Li, MD, PHD

Role: CONTACT

0531-82169851

Facility Contacts

Lian Liu, MD, PHD

Role: primary

tounao@126.com

0531-82169851

Song Li, MD, PHD

Role: backup

songli@sdu.edu.cn

0531-82169851

Other Identifiers

SEARCH

Identifier Type: -

Identifier Source: org_study_id